News | January 11, 2023
Moderna to acquire Oriciro Genomics
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Acquisitions have the potential to add at least $1 billion in sales by 2028
Cipla and Ethris partner for the development of mRNA-based therapies
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Miravo to remain a Canadian controlled and operated company following closing of the transaction
As per the agreement, NSE-listed Vaishali Pharma Limited will take over the entire domestic and international marketing of Jark Pharma’s portfolio of quality based ayurvedic products
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
Subscribe To Our Newsletter & Stay Updated
